Why are global medical supply chains currently so vulnerable?
Structural weaknesses in the global production and distribution of pharmaceutical and medical technology products have been exposed by recent global health crises. The primary issue stems from a profound lack of data regarding the importation of essential raw materials and active pharmaceutical ingredients (APIs). Without real-time visibility into these early-stage inputs, authorities struggle to identify and react to potential disruptions before they manifest as retail shortages.
The complexity of these chains means that a single bottleneck in a remote part of the world can halt the production of life-saving treatments. This lack of transparency prevents a proactive rather than reactive response to supply shocks.
What does the market concentration look like for critical products?
Market concentration is exceptionally high for several key categories of medical supplies, often leaving national health systems dependent on a very small number of suppliers. The OECD report uses three specific case studies to illustrate this risk: injectable corticosteroids, influenza vaccines, and molecular influenza diagnostic kits.
Analyzing specific product dependencies
The analysis of injectable corticosteroids reveals a precarious pattern. While 84 companies in the EU possess the capability to provide these products, national markets typically rely on only one or two suppliers per active ingredient. This concentration is largely driven by procurement tenders, particularly since 76% of these sales are directed toward the hospital sector. For the active ingredients themselves, the dependency is even more pronounced: of the 20 companies identified as having supply certificates for corticosteroids sold in the EU in 2024, only six are located within the EU. The remaining suppliers are distributed between the USA (2), China (9), India (2), and Malaysia (1).
Influenza vaccines present a different type of risk. Production is heavily concentrated in the EU and the US, but the process is highly sensitive to timing. Because production must occur within strict seasonal windows, any delay in batch testing or regulatory release can lead to immediate shortages. Similarly, the production of molecular diagnostic kits is vulnerable due to its reliance on a vast array of specialized reagents and components sourced from diverse suppliers both inside and outside Europe, with market shares often remaining opaque.
How can international cooperation improve supply security?
No single nation can ensure its own medical supply security due to the inherently global nature of these networks. The OECD evaluates six categories of international cooperation mechanisms designed to expand supply, facilitate trade, and build resilience against acute crises.
- Broad Trade Agreements: These can diversify supply sources and expand production capacity, though they carry the risk of facilitating the offshoring of existing production capabilities.
- Strategic Partnerships: These have proven more flexible than broad agreements. In the critical raw materials (CRM) sector, targeted trade agreements have already increased trade between partners by 12%.
- Mutual Recognition Agreements (MRAs): These reduce the burden of inspections and facilitate market access. While effective for pharmaceuticals, the OECD notes that MRAs for medical technologies are currently lacking.
- Digitalization: Improving interoperability at borders can prevent administrative delays from worsening supply disruptions during crises.
While some regional initiatives in Africa and Latin America aim for self-sufficiency, they may actually support EU security by helping to decompress the global demand for pharmaceutical products.
What is the role of digital market intelligence?
A centralized Market Information System could significantly enhance the ability of regulators to manage crises by providing a diagnostic view of the supply landscape. Such a system would allow authorities to distinguish between different types of disruptions, which is essential for choosing the correct policy response.
The system would identify whether a shortage is caused by physical production constraints, coordination failures, or a sudden spike in demand. However, implementing such a system requires overcoming two major hurdles: commercial confidentiality and competition law. To address these, the OECD suggests an architecture for data aggregation that prevents individual company data from being disclosed, alongside the establishment of legal "safe harbors" to protect companies from antitrust issues during coordinated crisis responses.
What is the proposed pilot program for high-priority goods?
The OECD recommends launching a proof-of-concept pilot project focusing on 20 to 30 high-priority products. This pilot would test the feasibility of coordinated monitoring and response mechanisms in a controlled environment. After a 24-month review period, the results would determine whether the mechanism should be scaled up, narrowed in scope, or transformed into a more flexible coordination framework.
One potential tool within this framework is a joint procurement mechanism. If opened to partners outside the EU, this could secure supplies through pre-purchase agreements and guaranteed volumes, providing the stability needed for manufacturers to maintain consistent production levels even during periods of low demand.
Key takeaways
- Structural vulnerabilities in medical supply chains stem from a lack of data on raw material and active ingredient imports.
- The corticosteroid market shows high dependency, with 70% of API suppliers located outside the European Union.
- Strategic trade agreements have successfully increased critical raw material trade by 12% globally.
- A proposed pilot program would monitor 20-30 high-priority medical products over a 24-month period.
- Digital Market Information Systems are needed to distinguish between production limits and demand surges.
FAQ: Medical Supply Chain Resilience
Why are pharmaceutical shortages becoming more frequent?
Shortages are driven by structural problems in global production and distribution, alongside a lack of visibility into the supply of raw materials. When authorities cannot track the movement of active ingredients, they cannot predict or prevent disruptions before they impact patients.
How does market concentration affect drug availability?
High concentration means many countries rely on only one or two suppliers for specific medicines. If one supplier faces a production issue or a regulatory delay, there are no immediate alternatives, creating a high risk of widespread shortages in the hospital sector.
Can international agreements help secure medical supplies?
Yes, targeted strategic partnerships and Mutual Recognition Agreements (MRAs) can facilitate faster trade and reduce inspection burdens. These mechanisms help diversify supply sources and ensure that life-saving products can move across borders more efficiently during health crises.
What is a Market Information System in this context?
A Market Information System is a digital tool designed to provide real-time data on the availability of critical products. It helps regulators identify if a shortage is caused by manufacturing issues, logistics failures, or sudden increases in global demand.
How can digital technology prevent supply chain delays?
Digitalization improves the interoperability of border processes and documentation. By reducing the administrative burden and the need for physical inspections through digital verification, technology helps prevent bureaucratic bottlenecks from turning a minor delay into a major medical shortage.
Conclusion
Securing the future of healthcare requires a shift from reactive crisis management to proactive, data-driven resilience. The OECD's findings underscore that the current reliance on a small number of global suppliers for critical medicines like corticosteroids and vaccines creates unacceptable risks. By implementing digital market intelligence, fostering strategic international partnerships, and testing coordinated procurement through pilot programs, health authorities can build a more robust buffer against disruption. Ultimately, transparency in the early stages of the supply chain—from raw materials to finished products—is the most vital component in ensuring that essential medical supplies remain available to those who need them most.
